hemodialysis
- Antiviral AgentsRemoval of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo. Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining...
- Clinical TherapeuticsA Thrice-Weekly Ertapenem Regimen Is Practical for Hemodialysis Patients
A change of ertapenem dosage from 500 mg daily to thrice weekly, after each hemodialysis session, can maintain the plasma concentration above 2 mg/liter and be practical for hemodialysis patients.